多瑞醫藥(301075.SZ):成立全資子公司潛江多瑞藥業有限公司
格隆匯1月20日丨多瑞醫藥(301075.SZ)公佈,根據公司經營及戰略發展的需要,為加強公司競爭力,公司成立全資子公司潛江多瑞藥業有限公司,註冊資本2000萬元人民幣。
經營範圍:許可項目:藥品生產;藥品批發;藥品零售;獸藥生產;獸藥經營;藥品進出口(依法須經批准的項目,經相關部門批准後方可開展經營活動,具體經營項目以相關部門批准文件或許可證件為準)一般項目:中藥提取物生產;化工產品生產(不含許可類化工產品);化工產品銷售(不含許可類化工產品);專用化學產品製造(不含危險化學品);專用化學產品銷售(不含危險化學品);醫學研究和試驗發展;信息諮詢服務(不含許可類信息諮詢服務)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.